ORIC Pharmaceuticals Participates in Key Investor Conferences
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is actively engaging with the investment community through a series of upcoming conferences. As a clinical-stage oncology company, ORIC focuses on innovative treatments that target mechanisms behind therapeutic resistance, aiming to enhance patient outcomes across various cancer types. In September, ORIC's management will be participating in several high-profile investor conferences that provide an excellent platform for showcasing their progress and insights.
Citi's 2025 Biopharma Back to School Summit
One of the highlights includes participation in Citi's 2025 Biopharma Back to School Summit. ORIC's management will conduct a fireside chat on a dedicated panel allowing for in-depth discussions regarding their groundbreaking strategies. The chat is scheduled to take place on September 3, 2025, at 4:00 p.m. Eastern Time. This engagement provides a unique opportunity for investors to gain direct insights into ORIC's mission and impact.
2025 Wells Fargo Healthcare Conference
Following the Citi Summit, ORIC's team will also attend the 2025 Wells Fargo Healthcare Conference, participating in another pivotal fireside chat. Set for September 4, 2025, at 2:15 p.m. Eastern Time, this conference serves as an influential gathering for healthcare investors and industry players. ORIC’s presence highlights its commitment to transparency and investor relations.
Cantor Global Healthcare Conference 2025
On September 5, 2025, ORIC will take part in the Cantor Global Healthcare Conference, where management will once again engage in a fireside chat session at 8:35 a.m. Eastern Time. These discussions are crucial for fostering relationships with investors and are expected to provide insights into ORIC’s advancements in addressing cancer treatment challenges.
Morgan Stanley and Baird Global Healthcare Conferences
Moreover, the team will hold a series of one-on-one meetings during the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. This setting allows for personalized interactions, facilitating deeper dialogues on investment strategies and company initiatives. Additionally, ORIC will participate in the Baird 2025 Global Healthcare Conference on September 10, 2025, with another fireside chat scheduled for 1:25 p.m. Eastern Time.
Webcast Availability and Replays
Interested investors and individuals unable to attend can access webcasts of these fireside chats through the investor section of ORIC’s official website. Replays will be available for a period of 90 days post-event, ensuring that all interested parties have an opportunity to stay informed about ORIC's activities and innovations.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company devoted to enhancing the lives of patients by addressing therapeutic resistance in cancer. Its flagship product candidates, including ORIC-944 and enozertinib (also known as ORIC-114), are grounded in innovative science aimed at overcoming significant barriers in cancer treatment. ORIC-944 targets the polycomb repressive complex through its allosteric inhibition, particularly focusing on prostate cancer. In parallel, enozertinib offers targeted solutions for various genetically-defined cancers by selectively engaging with critical mutations.
With offices located in South San Francisco and San Diego, California, ORIC actively continues its mission to advance cancer therapies. For more detailed information, check out the ORIC Pharma website and consider following them on social media platforms like X and LinkedIn.
Frequently Asked Questions
What is ORIC Pharmaceuticals known for?
ORIC Pharmaceuticals specializes in developing innovative cancer treatments aimed at overcoming mechanisms of therapeutic resistance.
When will ORIC participate in the Citi Summit?
ORIC will participate in the Citi's 2025 Biopharma Back to School Summit on September 3, 2025.
How can I access the webcasts of ORIC’s conferences?
Webcasts of the fireside chats will be available through the investor section of the ORIC website, with replays for 90 days after each event.
What are ORIC’s main product candidates?
ORIC’s main product candidates are ORIC-944, aimed at treating prostate cancer, and enozertinib (ORIC-114), which focuses on various genetically defined cancers.
Where is ORIC Pharmaceuticals located?
ORIC Pharmaceuticals has offices in South San Francisco and San Diego, California.
